OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics is positioned favorably because its “Super Cycle” has re-accelerated product innovation after years of EU MDR compliance work, leaving a broad launch pipeline across Trauma & Deformity, Scoliosis, Specialty Bracing, and Enabling Technologies. The company is already seeing strong distributor enthusiasm, share gains from products like 3P Hip, PNP Tibia, and VerteGlide, and revenue growth of 13.3% year over year in 1Q26 to about $59.4 million, while FY26 revenue guidance of roughly $263 million to $267 million implies continued double-digit growth. Its outlook is further strengthened by higher-ASP, higher-margin launches, improving capital efficiency, expected adj. EBITDA of about $25 million, and expanding OPSB clinic and territory growth that should support profitability and operating leverage over time.

OrthoPediatrics is vulnerable to a mix of execution and competitive risks that could pressure both growth and profitability, especially if distributor productivity weakens or if Orthex, ApiFix, Pega Medical, Boston O&P, or MDOrtho underperform. Its emerging profitability could be delayed if management increases spending to chase growth, while larger and more entrenched orthopedic competitors could further constrain share gains. Despite revenue estimated at $315.5M and a 1.6x NTM EV/Sales valuation, the thesis remains negative because a slower product pipeline, customer or distributor loss, and limited intellectual property and long-term clinical data reduce confidence in sustained upside.